The regimen tucatinib, capecitabine and trastuzumab was approved in April 2020 for adult patients with advanced unresectable or metastatic HER2+ BC, including patients with BrM, who have received one or more prior anti‐HER2‐based regimens in the metastatic setting. Here, ERBB2 is linked to breast cancer.